Clinical Trials Logo

T-All clinical trials

View clinical trials related to T-All.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06136364 Recruiting - Clinical trials for T-lymphoblastic Lymphoma

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

Start date: August 15, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

NCT ID: NCT05398614 Recruiting - Lymphoma, T-Cell Clinical Trials

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Start date: May 1, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.

NCT ID: NCT04785833 Recruiting - T-ALL Clinical Trials

CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia

Start date: March 4, 2021
Phase: N/A
Study type: Interventional

Patients with acute leukemia derived from T lymphocytes have the characteristics of high expression of CD7 antigen, such as acute T lymphocyte leukemia (T-ALL).CAR-T therapy is to genetically modify the patient's T lymphocytes to target and eliminate tumor cells in a major histocompatibility complex-independent manner. CAR-T cells are costimulatory molecules that include single-chain antibodies (scFv) that recognize tumor-specific antigens, hinge regions, transmembrane regions, intracellular signaling regions (immunoreceptor tyrosine activation motif ITAM), and intracellular signaling regions. The chimeric antigen receptor of CD28 or CD137(4-1BB) conduction domain is expressed in a lentiviral vector, and the vector is transfected into autologous T cells, so that the modified CAR-T cells have targeting and specificity Recognizes and kills cancer cells expressing tumor antigens, and can proliferate and activate in vivo, but has no effect on cells that do not express the antigen